<DOC>
	<DOCNO>NCT01955603</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) NNC0215-0384 administered subject moderate severe rheumatoid arthritis ( RA ) concomitantly treat methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Trial Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics NNC0215-0384 Administered Subjects With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Male female , age 18 75 year ( year inclusive ) , Russia : Age 1865 year ( year inclusive ) Moderate severe RA , confirm Disease Activity Score base 28 joint Creactive protein ( DAS28 ( CRP ) ) equal 4.5 minimum five tender five swollen joint base 28 joint count ( joint score tender swollen ) MTX ( 1025 mg/week inclusive ) least 16 week , unchanged dose least 6 week prior screen randomisation Females childbearing potential must postmenopausal least 1 year confirm folliclestimulating hormone ( FSH ) equal 26.7 U/L surgically sterile Past current inflammatory joint disease RA ( e.g . gout [ crystal proven ] , psoriatic arthritis , juvenile idiopathic arthritis , reactive arthritis Lyme disease Any active ongoing chronic infectious disease ( e.g . chronic osteomyelitis , chronic pyelonephritis ) within 4 week prior randomisation Clinically significant cardiac cardiovascular disease Past current malignancy Evaluation tuberculosis screen indicative latent active tuberculosis ( TB )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>